The report provides a detailed analysis essential for establishing an eslicarbazepine acetate production plant. It encompasses all critical aspects necessary for eslicarbazepine acetate production, including the cost of eslicarbazepine acetate production, eslicarbazepine acetate plant cost, eslicarbazepine acetate production costs, and the overall eslicarbazepine acetate production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an eslicarbazepine acetate production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Eslicarbazepine Acetate is a modern anticonvulsant medication with key roles in epilepsy management. It is a prescription medicine mainly used to manage partial-onset seizures in patients with epilepsy. It mainly serves as an add-on treatment for partial-onset seizures in patients who do not respond well to standard therapies. It works by stabilising electrical activity in the brain, which helps reduce the frequency and severity of seizures. It is also used in controlling focal seizures, both simple and complex, in adults and children aged 4 years and older. It helps reduce seizure frequency when other drugs fall short. It also finds its application in the treatment of epilepsy cases in combination with other antiepileptic drugs, depending on the severity of the condition. It is also used in clinical studies related to neurological disorders and seizure management.
The market for eslicarbazepine acetate is primarily driven by its application as oral anti-epileptic medicines intended for long-term epilepsy treatment, which boosts its demand in the pharmaceutical industry. Its application as monotherapy or as adjunctive therapy for the treatment of partial-onset seizures in patients aged 4 years and older significantly supports its demand in the medical and healthcare sectors. Its usage as an effective anticonvulsant alongside other seizure-control medications, depending on patient needs, further contributes to its demand in the medical and pharmaceutical industries. Its demand in the healthcare sector for consistent seizure control in both children and adults to support daily functioning and quality of life also drives its market growth.
Its involvement in ongoing studies for conditions like neuropathic pain, migraines, and certain psychiatric disorders, such as mania, also adds to its demand in the pharmaceutical research and biotechnology industries. Developments in production efficiency, supplier performance, environmental compliance, and streamlined logistics significantly impact industrial eslicarbazepine acetate procurement. Factors such as the cost and availability of major intermediates, adherence to international regulatory standards, and patent exclusivity considerations also influence global procurement decisions for eslicarbazepine acetate.
Raw Material for Eslicarbazepine Acetate Production
According to the eslicarbazepine acetate production plant project report, the major raw materials for eslicarbazepine acetate production include oxcarbazepine, (S,S)-TsDAEN, formic acid, acetic anhydride, DMAP, pyridine, and isopropanol.
Production Process of Eslicarbazepine Acetate
The extensive eslicarbazepine acetate production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of eslicarbazepine acetate begins with the asymmetric reduction of commercially available oxcarbazepine using a ruthenium catalyst system and (S,S)-TsDAEN ((S,S)-N-p-toluenesulfonyl-1,2-diaminocyclohexane) with formic acid as the reductant. The reaction is carried out in a mixed solvent system under reflux, followed by gradual cooling and crystallisation to form the chiral alcohol intermediate with high enantiomeric purity. Then, this alcohol is acetylated using acetic anhydride in the presence of DMAP and pyridine under reflux in dichloromethane. Further processing and crystallisation from isopropanol results in the formation of highly pure eslicarbazepine acetate as the desired product. In an alternative method, oxcarbazepine is first converted to a vinyl acetate intermediate. Then, the obtained intermediate undergoes asymmetric hydrogenation using a preformed chiral catalyst to directly give eslicarbazepine acetate as the final product in high yield and optical purity.
Eslicarbazepine Acetate is the acetate ester prodrug of eslicarbazepine, and it acts as a voltage-gated sodium channel blocker with anticonvulsant activity. It appears as a white to almost white crystalline powder that is freely soluble in dimethyl sulfoxide and dichloromethane but practically insoluble in water. The molecular formula of the compound is C17H16N2O3, and its molar mass is 296.32 g/mol. Its density is approximately 1.3 g/cm³, and its melting point is around 183–185 °C. The boiling point of the compound is around 427.4 °C at 760 mmHg, and its flash point is approximately 212.3 °C. The compound comes with a warning signal word, as it may cause skin and eye irritation and respiratory tract irritation upon exposure. It is sold under the brand names Aptiom and Zebinix, and it is recommended to wear a dust mask and eye protection while handling the compound.
